The nuclear receptor coactivator amplified in breast cancer 1 (AIB1) and its more active isoform AIB1-D3 are overexpressed in breast cancer and preneoplastic breast tissue. However, the impact of these proteins on the transcriptional activity of natural estrogens or selective estrogen receptor modulators (SERMs) has not been determined. Here we show that AIB1-D3 causes a significant increase in the efficacy of 17b-estradiol at both estrogen receptor-a (ER-a) and ER-b in ovarian, breast and endometrial cancer cell lines. AIB1-D3 also significantly increased the efficacy of the natural estrogen genistein at both ER-a and ER-b, whereas AIB1 had no effect on either the potency or efficacy of genistein at either receptor. The estrogenic efficacy of the partial agonist tamoxifen was significantly increased in all cell lines at ER-a by overexpression of AIB1-D3 both on transfected and endogenous estrogen responsive genes. In contrast, overexpression of AIB1 or AIB1-D3 had no effect on the potency or efficacy of the SERM raloxifene. We conclude that overexpression of the AIB1-D3 isoform will increase the estrogenicity of a variety of natural and pharmacologic compounds in tissues that develop hormone-dependent neoplasias and overexpression of these cofactors may be a contributing factor to the hormonedriven development of neoplasia and to antiestrogen resistance of breast cancers.
Introduction
Estrogens exert many of their effects through direct binding to a nuclear estrogen receptor (ER). After ligand binding, the ER binds as a dimer to a cognate estrogen response element (ERE) present in the gene promoter regions of estrogen responsive genes. Selective estrogen receptor modulators (SERMs) have tissuespecific agonist or antagonist effects leading to the idea that the classical model of ER action is more complex.
The discovery of a second ER gene (ER-b), which has a different tissue distribution relative to ER-a, has gone some way to explaining tissue-specific effects (Couse et al., 1997; Kuiper et al., 1997) . In addition, the recently discovered tissue-specific nuclear receptor coactivators and corepressors, which can modify the transcriptional activity of the ER and other nuclear receptors, also play a role in SERM activity (McKenna et al., 1999) .
The p160/SRC (steroid receptor coactivator) family is a family of coactivators involved in the regulation of steroid receptor-mediated transcription (McKenna et al., 1999) . There are three described p160 genes: SRC-1 (Onate et al., 1995) , SRC-2 or TIF-2 (GRIP1) (Voegel et al., 1996) , and amplified in breast cancer 1 (AIB1) (Anzick et al., 1997) , also known as ACTR/RAC3/ TRAM-1/SRC-3 Li et al., 1997; Takeshita et al., 1997; Suen et al., 1998) . Mapping studies have demonstrated that these coactivators have several similar features including a receptor interaction domain (RID), a basic helix-loop-helix/Per/Arnt/Sim homology (bHLH/PAS) domain and a CBP cointegrator interaction site (McKenna et al., 1999; Glass and Rosenfeld, 2000; Leo and Chen, 2000) . Of interest for breast cancer was the discovery that an area of chromosome 20q, a region frequently amplified in breast cancer, harbored the nuclear receptor coactivator gene AIB1 (Guan et al., 1996) . The AIB1 gene is amplified in 5-10% of breast cancers and the mRNA and protein are overexpressed in approximately 30% of breast tumors (Anzick et al., 1997; Bautista et al., 1998; Kurebayashi et al., 2000; Murphy et al., 2000; Bouras et al., 2001; List et al., 2001b) . We have determined, using a regulatable AIB1-directed ribozyme, that downregulation of endogenous AIB1 levels results in loss of estrogen induction of MCF-7 breast cancer cell proliferation in vivo and in vitro (List et al., 2001a) . AIB1 has been shown to directly interact with the ER in breast cancer cells (Tikkanen et al., 2000) . Consistent with this, deletion of the AIB1 gene in mice leads to reduced development of the mammary gland (Xu et al., 2000) .
An important finding was that a splice variant of AIB1, in which exon 3 is deleted (AIB1-D3), is overexpressed in MCF-7 breast cancer cells, as well as in breast tumor tissue (List et al., 2001b; Reiter et al., 2001) . The predicted protein product from this isoform is an N-terminally truncated version of AIB1 that has a deleted bHLH domain and most of the PAS region removed (Reiter et al., 2001) . Alterations in this domain are of interest since it has been shown that the bHLH/ PAS domain can mediate homodimerization between family members and in this case may mediate crosstalk between nuclear receptors and bHLH/PAS family members that have wide ranging effects in cellular growth control (Aravind and Ponting, 1997; Fan and Crews, 1999) . Surprisingly, overexpression of the AIB1-D3 isoform potentiates ER, progesterone receptor (PR) and epidermal growth factor (EGF) induction of transcription to a much greater extent than AIB1 (Reiter et al., 2001) , suggesting that the overexpression of this isoform may well play a role in sensitizing breast cancer cells to hormones during breast cancer development.
In this study, we sought to determine how overexpression of AIB1 or the AIB1-D3 isoform affected the pharmacology of natural estrogens and SERMs at the ER-a or ER-b. Our data indicate that in breast and endometrial cancer cells and in ovarian cells, hence cells of different endocrine origins, overexpression of AIB1-D3 can cause significant increases in the estrogenic efficacy of natural estrogens and the SERM, tamoxifen, at both ER-a and ER-b. Interestingly, overexpression of either AIB1 or AIB1-D3 did not increase the estrogenic efficacy of raloxifene, suggesting that the conformational changes induced by estrogens or partial agonists (Paige et al., 1999) that allow interaction with AIB1-D3 do not occur in the presence of raloxifene. Our data, showing the effects on endogenous genes, also imply that overexpression of AIB1-D3 could enhance estrogeninduced proliferative activity of selected compounds, thus contributing to the development of hormonedependent tumors and to antiestrogen resistance.
Results

Effects of AIB1-D3 on the activation of ER-a
We previously reported that AIB1-D3, at saturating levels of 17b-estradiol, can induce a larger estrogen response in a transcriptional assay than full-length AIB1 (Reiter et al., 2001) . As physiologic hormone interactions often do not take place at saturating hormone levels, we expanded this study and evaluated the response of AIB1-D3 to different concentrations of 17b-estradiol, at both ER-a and ER-b. We transfected CHO cells with an expression vector for ER-a, a luciferase reporter plasmid containing a multimerized ERE and with expression vectors encoding either fulllength AIB1 or AIB1-D3. The transfection of cells with the AIB1 expression vector resulted in a 1.3-fold increase in estrogen activation of luciferase activity, whereas transfection with the AIB1-D3 expression vector resulted in a significant 1.9-fold increase in the estrogen response (Figure 1a) , thereby confirming the increased efficacy reported by us earlier (Reiter et al., 2001) . It is of note that significantly less protein is produced from the transfected AIB1-D3 vector than from the full-length AIB1 (Figure 1a , Western blot inset), implying that the increase in response on a molar basis is even greater for AIB1-D3. Neither AIB1 nor AIB1-D3 caused a left shift or a change of the slope of the dose-response curve of 17b-estradiol at ER-a and thus only impact on the efficacy and not the potency. The above dose-response curves were generated in the presence of the estrogen antagonist ICI 182,780 at low concentrations to minimize the estrogenic background from serum. We performed similar experiments without ICI 182,780 and observed comparable results, although estrogen induction was lower due to increased background, and the dose-response curve was left shifted in the absence of the antagonist. The impact on efficacy by AIB1 and AIB1-D3 did not change relative to each other (data not shown). In addition, the amount of DNA transfected is optimal. This was determined by a titration curve, which showed that with lesser amounts of DNA coactivation decreased accordingly (data not shown). We therefore chose 1.5 mg of DNA as optimal for all further transfection experiments.
Effects of AIB1-D3 on the activation of ER-b ER-b is widely expressed in normal and malignant tissues (Couse et al., 1997; Kuiper et al., 1997; Roger et al., 2001) , but the tissue distribution differs from ERa (Nilsson and Gustafsson, 2002) . Through ER-b, 17b-estradiol can regulate different sets of genes (Couse et al., 1997) and can oppose the effect of ER-a (Hall and McDonnell, 1999) . We therefore examined whether AIB1 and AIB1-D3 can act as coactivators for ER-b. Using the same experimental design as for ER-a, quantitatively similar results were seen, with a 1.5-fold 5 mg) , or pcDNA3-AIB1-D3 (1.5 mg) together with an expression vector for human ER-a (50 ng), an ERE-luciferase reporter plasmid (500 ng), and pRL-CMV (0.1 ng). Cells were incubated for 20 h with the indicated concentrations of 17b-estradiol in the presence of 10 nM ICI 182,780 before determining luciferase activity. Relative light units were normalized against Renilla luciferase acitivity. The inset shows immunoblot analysis of transfected cell lysates that were fractionated on 4-20% polyacrylamide gradient gels and probed with an antibody to AIB1. (b) Cells were transfected, treated and assayed as in (a) with the exception that the ER-a vector was replaced with a vector for ER-b (50 ng). Data represent mean7s.e. of values from three independent experiments, each performed in triplicate. * , þ Po0.01 versus control; # Po0.01 versus AIB1
Effect of an AIB1 coactivator isoform on estrogenic activity R Reiter et al increase in luciferase activity when AIB1 was cotransfected, and a 2.8-fold increase when AIB1-D3 was transfected ( Figure 1b) . A small, but insignificant left shift of the dose-response curve with overexpression of either AIB1 or AIB1-D3, indicates a slight increase in potency at ER-b.
Effects of AIB1-D3 on genistein-mediated activation of ER
Genistein, a phytoestrogen present in soy, produces a wide variety of pharmacological effects and may be responsible for some of the reported effects of soy in the diet. Dietary ingestion of soy has been linked to prevention of breast cancer (Zava and Duwe, 1997; Lamartiniere et al., 2002) and, although the reason for this association remains unclear, it may be due to the estrogenic effects of the genistein in soy. It was therefore of interest to determine the impact of overexpression of the coactivators AIB1 and AIB1-D3 on the estrogenic activity of genistein. Transfection of CHO cells with ER-a, an ERE-luciferase reporter and full-length AIB1 showed no significant increase in reporter activity over control-transfected cells in the presence of genistein ( Figure 2a ). However, when AIB1-D3 was cotransfected, genistein activated the reporter 1.6-fold higher than control-transfected cells to a maximal 70-fold induction of the promoter, thus enhancing the efficacy of genistein. On the other hand, the potency of genistein at ER-a was not altered by the coactivators. Similar results were observed with ER-b ( Figure 2b ). In contrast, transfection of AIB1 did not increase reporter activation in the presence of genistein versus control, whereas transfection of AIB1-D3 augmented the response 1.7-fold over control ( Figure 2b ) without effect on the potency of genistein. From this we conclude that AIB1-D3 augments estrogenic activity of natural chemopreventive agents such as genistein at relevant serum concentrations in the high nanomolar range (Zava and Duwe, 1997).
Role of AIB1 and AIB1-D3 in breast cancer cells
The previous experiments were carried out in CHO cells, which have low background levels of AIB1. To determine if AIB1 or AIB1-D3 have an impact on the efficacy of 17b-estradiol in cells with endogenous AIB1, we tested the effects of transfection of these constructs in MCF-7 breast cancer cells. These cells harbor the 20q AIB1 gene amplicon and express both AIB1 and AIB1-D3 (Reiter et al., 2001) . In these cells, overexpression of AIB1 had no impact on endogenous ER induction of transcription whereas AIB1-D3 caused a 2.6-fold increase in 17b-estradiol responsiveness (Figure 3) . Thus, the increased efficacy of ER-a with AIB1-D3 that we observed in CHO cells is preserved in breast cancer cells.
Role of AIB1-D3 in endometrial cancer cell lines
Since expression of cofactors is tissue-specific and different subsets of cofactors can alter hormone responses, we investigated the role of AIB1 and AIB1-D3 in endometrial cancer cells. Endometrial cancer cell lines show a wide range of expression of AIB1-D3, with the lowest levels in Ishikawa cells (about 1% compared to full-length AIB1), medium levels in Hec1A cells, and the highest levels in RL95-2 cells (about 10% compared to full-length AIB1) (data not shown). Therefore, to minimize the effects of endogenous AIB1-D3 we used Ishikawa cells for further experiments. We transfected Ishikawa cells in a similar fashion as described above for CHO cells using a single, saturating dose of 17b-estradiol or genistein for treatment. AIB1 increased the estrogen response with cotransfected ER-a by 1.4-fold, in the presence of 17b-estradiol, whereas AIB1-D3 increased the activity 2.2-fold ( Figure 4a ). AIB1-D3 also increased the genistein response by 1.8-fold, while fulllength AIB1 had no significant effect (Figure 4b ). Upon Effect of an AIB1 coactivator isoform on estrogenic activity R Reiter et al cotransfection with ER-b, in the presence of 17b-estradiol, AIB1 caused a 1.4-fold increase in reporter activity versus a 1.7-fold increase with AIB1-D3 (Figure 4c ). With genistein, AIB1-D3 caused a 2.1-fold increase in activity (Figure 4d ), thus demonstrating that AIB1-D3 is also a more effective coactivator for estrogens in endometrial cancer cells.
AIB-D3 selectively increases the estrogenic activity of 4OH-tamoxifen
Tamoxifen is an effective treatment for ER positive breast cancer, however, most responsive tumors will eventually acquire resistance. Furthermore, tamoxifen displays a tissue-selective pharmacology; it is an agonist in some tissues (uterus, bone, liver, and the cardiovascular system) and an antagonist in other tissues (brain and breast) (Jordan, 2002) . Both effects, the selective pharmacology and the tumor resistance, could be produced by differential expression of coregulators, which have been shown to be tissue-specific and functionally distinct. We therefore examined the effect of AIB1-D3 on the estrogenic response to 4OH-Tamoxifen (OHT) (the active metabolite of tamoxifen), in CHO, MCF-7, and Ishikawa cells ( Figure 5 ). The cells were transfected with an expression vector for ERa, a luciferase reporter plasmid containing an ERE and with expression vectors encoding either full-length AIB1 or AIB1-D3. When treated with OHT, reporter activity in AIB1-transfected CHO (Figure 5a ) and MCF-7 cells (Figure 5c ) did not increase compared to controltransfected cells. However, when AIB1-D3 was transfected, luciferase activity increased 1.5-fold in CHO cells and 2.1-fold in MCF-7 cells treated with OHT (versus control-transfected cells) (Figure 5a, c) . In OHT-treated Ishikawa cells, cotransfection with AIB1 resulted in an increase of reporter activity (1.7-fold over controltransfected cells), whereas the transfection of AIB1-D3 further augmented luciferase activity 2.3-fold over control (Figure 5e ). Raloxifene is another SERM currently approved for treatment of osteoporosis and with potential use in the prevention of breast cancer. In contrast to OHT, overexpression of either AIB1 or 
Effects of AIB1-D3 on the transcription of endogenous estrogen responsive genes
The previous experiments were all carried with a transfected promoter, which is not in the context of native chromatin. To determine if AIB1-D3 also causes increased transcription of endogenous estrogen responsive genes, we examined mRNA levels of Cathepsin D (CATD) and Encoding ER-binding fragment-associated antigen 9 (EBAG9) by real-time RT-PCR in response to estrogen and tamoxifen in the presence of AIB1 or AIB1-D3. Both CATD and EBAG9 harbor classical estrogen responsive elements in their promoters (Augereau et al., 1994; Watanabe et al., 1998) . When AIB1 is transfected into MCF-7 cells estrogen-induced transcription of CATD and EBAG9 is only slightly higher compared to the control plasmid ( Figure 6 ). However, transfection of AIB1-D3 surprisingly results in a significant increase of transcription of the target genes. When cells are treated with OHT, AIB1-D3 also increases the stimulation of transcription of CATD and EBAG9 compared to AIB1 or control plasmid to levels equivalent to17b-estradiol. These results demonstrate that the effects seen in a luciferase reporter assay can be replicated in endogenous estrogen responsive genes, and that overexpression of the AIB1-D3 isoform would induce increased estrogenic activity of partial agonists.
Discussion
The data presented in this study confirm and extend our previous findings that, despite its low expression levels, AIB1-D3 is a significantly better coactivator of ER-amediated responses not only in CHO cells, but also in breast and endometrial carcinoma cell lines. This result has implications for breast cancer, suggesting that tumors that express elevated levels of this isoform will be very responsive to endogenous estrogenic stimulation of proliferation and other pro-oncogenic responses mediated through ER-a or ER-b. Interestingly, the estrogenic stimulus is also amplified for a phytoestrogen such as genistein, which is found in soy, which may also lead to increased estrogenic stimulus to the breast in a subset of tumors that contain amplified AIB1 and AIB1-D3. Of significant interest for breast cancer therapy is the observation that the estrogenic activity of the SERM tamoxifen was increased at ER-a in breast cancer and endometrial cancer cell lines. Tamoxifen antagonizes estrogen responses in human mammary epithelium, however, resistance to antiestrogen therapy occurs frequently. The mechanism of this increased resistance is not known but a number of investigators have suggested that alteration of cofactors, such as AIB1, required for ER action might explain the acquisition of antiestrogen resistance (Osborne et al., 2003) . Although full-length AIB1 caused no significant increase in tamoxifen's estrogenic activity in any of the cell lines we tested, AIB1-D3 caused a significant increase in the estrogenic activity of tamoxifen in both MCF-7 and Ishikawa cells. This suggests that overexpression of this isoform might contribute to the development of antiestrogen resistance in breast cancer cells. The mechanism of the increased transcriptional activity of the AIB1-D3 isoform is not known. Experiments comparing the interactions of AIB1 versus AIB1-D3 to components of the transcription complex such as the receptor or CBP have not to date revealed major differences in their binding interactions (unpublished data). Another mechanism that may explain the increased activity of the AIB1-D3 isoform is that loss of the bHLH/PAS dimerization domain leads to loss of interaction with an endogenous repressor (Reiter et al., 2001) .
Increased AIB1-D3 may also contribute to the increased levels of endometrial carcinoma seen in tamoxifen-treated patients (Fisher et al., 1994) . Although AIB1 levels in endometrial cancer cells are lower than in breast cancer cells and SRC-1 seems to play a more predominant role in the endometrium (Shang and Brown, 2002) , expression of the potent AIB1-D3 isoform may increase the estrogenic efficacy of tamoxifen in the endometrium. Indeed it is possible that human endometrial carcinoma contains significant levels of the AIB1-D3 isoform and we are currently examining this in human tumors.
Interestingly, neither AIB1 nor the AIB1-D3 isoform increased the estrogenic activity of the SERM raloxifene at ER-a, suggesting that neither AIB1 nor AIB1-D3 overexpression would play a role in the development of resistance to this SERM. Differences in the ability of the AIB1-D3 isoform to coactivate SERMs may explain tumors in which no crossresistance between these compounds develops. Biochemically, our data suggest Figure 6 Effects of AIB1 and AIB1-D3 on the expression of CATD and EBAG9 in MCF-7 stimulated with estrogen and OHT. Cells were plated at 25% confluence in six-well plates in the presence of 10 nM ICI 182,780 in IMEM supplemented with 5% FBS that had been treated with dextran-coated charcoal. After 24 h, cells were transfected with either empty pcDNA3 vector (3 mg) (Control), pcDNA3-AIB1 (3 mg) or pcDNA3-AIB1-D3 (3 mg). The next day cells were treated with either ethanol alone, 100 nM 17b-estradiol or1 mM OHT for 2 h before RNA was harvested and CATD (a) and EBAG 9 (b) expression were measured by real-time RT-PCR. mRNA levels were normalized by GAPDH mRNA expression, and the normalized values were then expressed relative to that of control cells transfected with pcDNA3 and treated with ethanol alone. Data represent mean7s.e. of values from two independent experiments, each performed in duplicate. *Po0.05 versus the corresponding value for control cells Effect of an AIB1 coactivator isoform on estrogenic activity R Reiter et al that the coactivator binding interface of the ER-a, when bound to tamoxifen, can still significantly interact with the exposed LXXLL motifs of the AIB1-D3, but not those of AIB1. In contrast, the binding interface is significantly conformationaly different in the presence of raloxifene, thus preventing interaction with either AIB1 or AIB1-D3. Protein crystallography has revealed that estrogen agonists and SERMs induce unique conformational states of the ER (Shiau et al., 1998) . In the case of estrogen agonists and partial agonists, this may confer preferential binding of certain coactivators or, in the case of antagonists, will prevent coactivator binding and favor corepressor binding (Shiau et al., 1998) More recently it has been reported that differences in the interactions of OHT or raloxifene at amino acid 351 of the ER-a cause distinct differences in the estrogen-like action at activating function 2b (Liu et al., 2002) . Differences in ER-a confirmation in this domain may mediate changes in AIB1 or AIB1-D3 interactions which could differentially enhance estrogen function. It also should be noted that since it is known that raloxifene is an estrogen in bone, this suggests that other factors that play a role in its estrogenic activity are not present in MCF-7, CHO or Ishikawa cells.
It had previously been reported that AIB1 (SRC-3) could significantly coactivate ER-a but had little effect on ER-b (Suen et al., 1998) . Therefore, it is somewhat surprising that our data instead show that overexpression of AIB1 has little effect on the efficacy of estrogens or partial agonists at ER-a or ER-b. However, the AIB1-D3 isoform increased estrogenic efficacy of 17b-estradiol and genistein at both ER-a and ER-b in all the cell lines studied. ER-b is not expressed highly in malignant breast tissue and its expression appears to go down with progressive malignancy (Roger et al., 2001, 4647) , therefore its role in the development of antiestrogen resistance may be limited. However, ER-b is expressed at higher levels in bone where raloxifene, and to some extent tamoxifen, cause reversal of osteoporosis. To date, the levels of AIB1 and AIB1-D3 in the various cell types of the bone have not been described and it remains to be seen whether these coactivators play a role in estrogenic activity in bone or in other tissues where ER-b is high.
The effect of overexpression of coactivators on the pharmacology of other steroids, such as glucocorticoids, has been extensively examined and in general, an increase in efficacy coupled with a significant decrease in potency is observed, especially for agonists and partial agonists of the glucocorticoid receptor (Szapary et al., 1999) . However, in our study of ER-a and ER-b, although small changes in EC 50 were observed, the general effect of overexpression of the AIB1-D3 isoform was an increase in the efficacy of the estrogenic or partial agonist ligands at both ER-a and ER-b. These differences are clearly reflected in changes in endogenous gene expression as seen with the RT-PCR of both EBAG9 and CATD. This suggests that the coactivator complexes and rate-limiting steps of activation are different among nuclear receptors.
Materials and methods
Reagents 17b-estradiol, OHT and genistein were purchased from SigmaAldrich (St Louis, MO, USA). Raloxifene was provided by VC Jordan (Northwestern University, Chicago). ICI 182,780 was purchased from Tocris (Ballwin, MO, USA). Media, fetal bovine serum (FBS) and Lipofectamine were purchased from Life Technologies, Inc. (Gaithersburg, MD, USA).
Plasmids
The expression vector for human ER-a was provided by P Chambon (CNRS, France). The firefly luciferase reporter plasmid containing the ERE from the Xenopus vitellogenin gene was provided by VC Jordan (Northwestern University, Chicago) and the Renilla luciferase vector (pRL-CMV) was from Promega (Madison, WI, USA). The expression plasmids for AIB1 and AIB1-D3 have been described earlier (Reiter et al., 2001) . The control plasmid pcDNA3 was purchased from Life Technologies, Inc. (Gaithersburg, MD, USA).
Cell culture
All cell lines were obtained from the tissue culture core facility of the Lombardi Cancer Center. MCF-7 cells were cultured in Iscove's modified Eagle's medium supplemented with 10% FBS. Ishikawa cells were grown in Mimimum Essential Medium Alpha that was supplemented with 15% FBS. CHO cells were maintained in Ham's F-12 nutrient mixture supplemented with 10% FBS.
Transient transfection and reporter gene assays
Cells were plated at 25% confluence in 12-well plates and were cultured for 24 h at 371C under 5% CO 2 in the appropriate medium supplemented with 5% FBS that had been treated with dextran-coated charcoal. The medium was then replaced with IMEM containing Lipofectamine Plus and expression and reporter plasmids as indicated. After incubation for 5 h, the medium was replaced with medium containing 5% dextran-coated charcoal-treated FBS and nuclear receptor ligands. Cells were incubated for 24 h and then disrupted in passive lysis buffer (Promega). A measure of 20 ml of the resulting cell extract were assayed for both firefly and Renilla luciferase activities with the Dual-Luciferase reporter assay system (Promega).
Immunoblot analysis
Whole cell extracts were prepared as described previously (Harris et al., 2000) , and equal portions (30 mg of protein) were resolved on denaturing 4-20% polyacrylamide gradient gels containing Tris-glycine. The separated proteins were transferred to a nitrocellulose membrane and then subjected to immunoblot analysis with a 1 : 500 dilution of a mouse monoclonal antibody specific for amino acids 376-389 of human AIB1 (Transduction Laboratories, Lexington, KY, USA), horseradish peroxidase-conjugated goat antibodies to mouse immunoglobulin (1 : 10 000 dilution; Amersham Pharmacia Biotech, Piscataway, NJ, USA), and enhanced chemiluminescence reagents (Amersham Pharmacia Biotech).
Real-time RT-PCR
Cells were plated at 25% confluence in six-well plates and were cultured in the presence of 10 nM ICI 182 780 for 24 h at 371C under 5% CO 2 in IMEM supplemented with 5% FBS that had been treated with dextran-coated charcoal. Cells were then transfected with an expression construct for pcDNA3, AIB1 or AIB1-D3 by using Lipofectamine 2000 (Invitrogen Corp.) according to the manufacturer's instructions. At 24 h after transfection wells were treated with either ethanol alone, 100 nM of 17b-estradiol or 1 mM of OHT for 2 h. The RNeasy Mini Kit (Qiagen) was used for extraction and DNAse treatment of total RNA. Real-time RT-PCR was performed using the SuperScript One-Step RT-PCR System (Invitrogen Corp.). Samples were reverse transcribed at 501C for 30 min, followed by a denaturing step at 951C for 5 min and 40 cycles of 30 s at 951C, 30 s at 551C and 60 s at 721C. Fluorescent data were collected during the 721C step using the Cycler iQ Detection System (Bio-Rad Laboratories, Inc.). The primers and probes for real-time reverse RT-PCR measurement were: Cathepsin D forward primer: GTACATGATCCCCTGTGA-GAAGGT; cathepsin D reverse primer: GGGACAGCTTG-TAGCCTTTGC; and cathepsin D probe: 6FAM-ACCCTGCCCGCGATCACACTGA-TAMRA. EBAG9 forward primer: GATGCACCCACCAGTGTAAAGA; EBAG9 reverse primer: AGTCAGGTTCCAGTTGTTCCAAAG; and EBAG9 probe: 6FAM-AGGAGGGAATGGGAATGTGG-CAACAC-TAMRA. GAPDH forward primer: CCCACA TGGCCTCCAAGGAGTA; GAPDH reverse primer: GTCT ACATGGCAACTGTGAGGAGG; and GAPDH probe: 6FAM-ACCCCTGGACCACCAGCCCCAGC-TAMRA.
Statistical analysis was carried out using the GraphPad Prism program (GraphPad Software, Inc., San Diego, CA, USA).
